TLR9 immunotherapy for stomach or appendix cancer spreading in the abdomen
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental immunotherapy that targets a protein called TLR9 to help your immune system fight cancer cells that have spread into the lining of your abdomen (peritoneal carcinomatosis). It's for people with colorectal or appendix cancer that has spread this way and may also have some limited spread to the liver or lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have colorectal or appendix cancer that has spread into the lining of your abdomen, called peritoneal carcinomatosis.
- Your cancer must be measurable by tests like scans, blood markers, or physical exam.
- Your doctor must expect you to live at least 12 more weeks.
- You must be able to take care of yourself most of the day (ECOG performance status 0, 1, or 2).
- Your kidney, liver, and blood counts must be within certain safe limits—your doctor will check these.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy followed by an immunotherapy drug (tislelizumab) for people with stomach or colon cancer that has certain genetic markers. It aims to prevent the cancer from coming back after surgery.
This trial tests if adding a probiotic (Lactobacillus rhamnosus M9) to standard radiation and immunotherapy can help people with advanced digestive system cancers. It aims to see if the combination is more effective and safer than the standard approach alone.
This trial tests a combination of low-dose radiation therapy, immunotherapy, and chemotherapy for people whose stomach or colon cancer has spread to the lining of the belly (peritoneal cavity). The goal is to see if this approach can help control the cancer.
This trial tests a combination of low-dose radiation, immunotherapy, chemotherapy, and intraperitoneal perfusion for gastric cancer that has spread to the abdominal lining and is not removable by surgery. It aims to see if this treatment can help control the cancer after first-line chemotherapy has stopped working.
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Hear when a new Malignant Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.